Lippo Healthcare and AstraZeneca sign agreement for investment in the Grande Baie region



John Lee, Managing Director and CEO of Lippo Limited, seated left, and Gwenael Meneux, Managing Director of AstraZeneca Hong Kong & Macao, seated right and standing left to right, Wing Chan, Executive Vice President, Corporate Finance and Development of Lippo Group, David Ng, Director of Lippo Asia Limited, Chris Chow, Senior Director of Government Affairs and Market Access of AstraZeneca Hong Kong pose for photos at a signing ceremony . (Photo courtesy of the Lippo Group)

Jakarta. Lippo Healthcare and pharmaceutical company AstraZeneca Hong Kong have signed a memorandum of understanding on medical care and hospital management collaboration aimed at serving a growing number of healthcare customers in the Greater Bay Area.

The Greater Bay Area (GBA), which includes Hong Kong, Guangdong and Macao, has a potential market of around 70 million people.

According to information released by local media, The Standard on Wednesday, this collaboration will focus on chronic disease management using cutting-edge technological innovations based on big data and the Internet of Things (IoT).

Gwenael Meneux, managing director of AstraZeneca Hong Kong and Macao, said 17% of GBA residents are now 65 years of age or older, resulting in a huge demand for chronic disease care and other health-related services. geriatrics – physiological conditions and diseases associated with old age.

“We hope to combine the advantages of our pharmaceutical company in medicine and treatment planning, with Lippo Healthcare’s experience in clinical management and medical education, to provide high quality medical services to people in GBA. Our collaboration will focus on chronic diseases, such as cardiovascular and respiratory diseases, and on oncology, ”said Meneux, quoted by The Standard.

Meneux said AstraZeneca and Lippo see the potential to establish metabolic management centers in more than 30 hospitals in China to meet the needs of elderly people susceptible to illnesses ranging from respiratory illnesses to diabetes and other metabolic diseases. .

He said these treatment centers would implement big data-based analysis to identify high-risk patients early and offer them preventative measures in advance. These would save patients time and also allow the treatment facilities to function optimally.

Meneux said Hong Kong’s reputation for high-quality medical services and a pioneer in the application of medical innovation should help build public confidence in new treatment methods in the field of ACS. , did he declare. In addition, potential clients of the medical center should have some knowledge of technology-based health services, as many private institutions in Hong Kong already have telemedicine services.

It is hoped that the convergence of laws and regulations or the unification of the system between Hong Kong and mainland China should expand the scope of medical services in the GBA area.

Lippo Healthcare owns and operates numerous hospitals, medical facilities and nursing homes in the Asian region. In China, Lippo is currently building two hospitals in Shenzhen and Changshu.

John Lee, CEO and Managing Director of Lippo Healthcare, said that Lippo’s experience in the management of clinics and medical facilities as well as in the field of medical education makes him a balanced partner for excellence in AstraZeneca in research and innovation.

Lee said he is confident that this collaboration could result in reliable and affordable health care for GBA residents.



Leave A Reply